Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Psilocybe cubensis* is a species of psychedelic mushroom whose principal active compounds are the alkaloids psilocybin and psilocin. Upon ingestion, psilocybin is rapidly dephosphorylated into psilocin, which acts as a high-affinity partial agonist at the serotonin 5-HT2A receptor. This interaction modulates glutamatergic neurotransmission in the prefrontal cortex, leading to profound alterations in consciousness and perception. In a clinical context, *Psilocybe cubensis* and its standardized extracts are being investigated for their potential to induce rapid and sustained antidepressant and anxiolytic effects, particularly in treatment-resistant populations. Research suggests that the "mystical-type experience" facilitated by these compounds may be a key mediator of therapeutic outcomes, potentially promoting neuroplasticity and the reorganization of dysfunctional neural circuits associated with mood and substance use disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psilocybe cubensis.